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Purpose. To determine the effect of epiretinal membranes (ERM) on the treatment response and the number of intravitreal
bevacizumab injections (IVB) in patients with neovascular age-related macular degeneration (nAMD). Methods. A retrospective
chart review was performed on 63 eyes of 63 patients. The patients were divided into AMD group (𝑛 = 35) and AMD/ERM
group (𝑛 = 28). Best corrected visual acuity (BCVA) and central retinal thickness (CRT), as well as the number of injections, were
evaluated. Results. There was a significant improvement in BCVA at 3 months for the AMD and AMD/ERM groups (𝑃 = 0.02,
𝑃 = 0.03, resp.). At 6, 12, and 18 months, BCVA did not change significantly in either of the groups compared to baseline (𝑃 > 0.05
for all). At 3, 6, 12, and 24 months, the AMD group had an improvement in BCVA (logMAR) of 0.09, 0.06, 0.06, and 0.03 versus
0.08, 0.07, 0.05, and 0.03 for the AMD/ERM group (𝑃 = 0.29, 𝑃 = 0.88, 𝑃 = 0.74, 𝑃 = 0.85, resp.). A significant decrease in CRT
occurred in both groups for all time points (𝑃 < 0.001 for all). The change in CRT was not statistically different between the two
groups at all time points (𝑃 > 0.05 for all). The mean number of injections over 24 months was 8.8 in the AMD group and 9.2 in
the AMD/ERM group (𝑃 = 0.76). Conclusion. During 24 months, visual and anatomical outcomes of IVB in nAMD patients were
comparable with those in nAMD patients with ERM with similar injection numbers.
1. Introduction
Neovascular age-related macular degeneration (nAMD) is
the leading cause of vision loss worldwide among people aged
50 years and older [1–3].
Vascular endothelial growth factor (VEGF) plays a major
role in choroidal neovascularization (CNV) secondary to
nAMD characterized by angiogenesis and increased vascular
permeability. This condition leads to abnormal fluid collec-
tion within or below the retina [4–6]. Since the first introduc-
tion of the off-label use of intravitreal bevacizumab (IVB) for
neovascular AMD in 2005, numerous studies have reported
the efficacy and safety of this treatment [7]. Regarding
ocular and systemic safety issues, as well as cost and patient
convenience concerns, clinical trials with flexible dosing
regimens have been released to allow for fewer injections of
bevacizumab and ranibizumab [8–10]. The PrONTO study,
which evaluated an optical coherence tomography (OCT)-
based retreatment regimen for ranibizumab in nAMD,
showed that it is possible to stabilize and improve visual
acuity with an as-needed dosing regimen while reducing the
number of injections over 24months [11]. Similarly, ABC trial
demonstrated that IVB was superior to standard care when
administered on an as-needed treatment regimen for every
six weeks after the initial loading phase of three injections
[12].
Idiopathic epiretinal membranes (ERMs) cause macular
structural changes such as retinal folds, vascular leakage,
macular thickening, cystoid macular edema, pseudohole for-
mation, foveal ectopia, and foveal detachment by tractional
forces on the retinal surface [13]. Both idiopathic ERMs and
nAMD are observed in the same age group and cause visual
2 The Scientific World Journal
acuity deterioration [14]. In clinical practice, the coexistence
of the aforementioned diseases in advanced age groups may
cause difficulties in the management of AMD. The study by
Pierro et al. identified the coexistence of an ERM in 26% of
eyes with nAMD using an SD-OCT system [15]. However, no
study has investigated whether ERM could adversely affect
the course of nAMD or change the treatment strategy.
In this retrospective study, we performed a comparative
assessment to determine whether the effects of IVB were
different between the nAMD patients with ERM and without
ERM on treatment response.
2. Methods
This is a retrospective study which included the patients who
had undergone IVB treatment for newly diagnosed treatment
näıve nAMD at Beyoglu Eye Training and Research Hospital
between July 2007 and January 2009. Approval for data col-
lection and analysis was obtained from the ethics committee
of the hospital, and all patients provided informed consent.
The methodology of the study was conducted in accordance
with the tenets of the Helsinki Declaration.
The inclusion criteria for the study were as follows: (1)
age of 50 years or more; (2) the presence of active leakage
pattern indicating subfoveal or juxtafoveal CNVon FA; (3) all
subgroups of CNV including predominantly classic or min-
imal classic/occult; (4) baseline best corrected visual acuity
(BCVA) of ≥20/400. Patients with coexisting diseases involv-
ing the posterior pole such as diabetic retinopathy, vascular
occlusions, inflammatory diseases, trauma, high myopia, vit-
reomacular interface diseases other than ERM, and cataract
development or progression during the follow-up were
excluded from the analysis. Patientswhohadhistory of ocular
surgery within the last 6months or had previously undergone
vitreoretinal surgery, intravitreal injection, or photodynamic
therapy were also excluded.
All patients underwent a complete ophthalmologic exam-
ination, which included BCVA testing with standardized
refraction using early treatment diabetic retinopathy study
(ETDRS) charts, a fundus examination with a 90-diopter
indirect lens after mydriasis, colour fundus photography, and
FA.
All patients received a loading dose of three consecutive
injections of bevacizumab (1.25mg/0.05mL) with 4 to 6
weeks intervals in the initial phase. Patients were then fol-
lowed up by 4 to 6 weeks intervals with clinical examinations
andwithOCT.After three initial loading doses, the indication
for intravitreal reinjectionswas based onVA loss (five ETDRS
letters ormore), an increase in central retinal thickness (CRT)
of at least 50 𝜇m from the lowest recorded value, newmacular
haemorrhage, or leakage on FA. In the eyes with ERM, if
the persistence of intraretinal fluid after re-injection of beva-
cizumab was seen, no additional injection was performed
until progressing edema occurred. Persistent serous retinal
pigment epithelial detachment (PED) was not a retreatment
criterion.
At follow-up visits, FA was repeated only when the cause
of VA deterioration could not be clarified with the clinical
examination andOCT. ForOCT imaging, time-domainOCT
was performed (Stratus OCT 3000, Carl Zeiss, Meditec Inc.,
Dublin, CA, USA) after mydriasis. CRT, defined as the mean
thickness of the neurosensory retina in a central 1mm diam-
eter area, was computed using OCTmapping software gener-
ated by the device.
Patients were divided into two groups based on the
presence or absence of accompanying ERM: AMD group
and AMD/ERM group. In the AMD/ERM group, in addition
to nAMD, ERM covering the central macular area which
was grade 3 (retinal vascular distortion and/or retinal folds)
based on the ophthalmoscopic examination was present [16].
The diagnosis of ERM was then confirmed by the presence
of a hyperreflective band indicating a preretinal membrane
adherent to the inner retinal surface, as observed on OCT.
All injections were performed under sterile conditions
after topical anesthesia and 10% povidone-iodine (Betadine;
Purdue Pharma, Stamford, CT) scrub was used on the lids
and lashes, and then 5% povidone-iodine was administered
on the conjunctival sac. IVB was injected through the pars
plana at 3.5mm to 4mm to the limbuswith a 27-gauge needle.
Patients were then instructed to consult the hospital if they
experience decreased vision, eye pain, or any new symptoms.
Data collected from the patients’ records included age,
gender, type of CNV (predominantly classic or minimal clas-
sic/occult), the presence of PED at baseline, and BCVA and
CRT at baseline and at the 3-, 6-, 12-, and 24-month follow-
up visits. Also, injectionnumbers at 24-month follow-upwere
recorded.
The primary outcome measures included the changes in
BCVA and CRT between baseline and 3-, 6-, 12-, and
24-month follow-up. Secondary outcome measure was the
number of injections at 24-month follow-up.
2.1. Statistical Analysis. Visual acuity was converted to loga-
rithm of minimum angle of resolution (logMAR) for statisti-
cal analysis. The mean changes in BCVA and CRT over time
were analyzed using one-way ANOVA with repeated mea-
sures. Fisher’s exact test was used to compare nominal param-
eters between the groups, and Mann-Whitney 𝑈 test was
used for continuous parameters. The statistical analysis was
performed using SPSS version (Version 15.0, SPSS Inc.,
Chicago, IL, USA). A 𝑃 value of less than 0.05 was considered
to be statistically significant.
3. Results
A total of 63 eyes of 63 patients were included in this
study. There were 35 patients (15 female and 20 male) in the
AMD group and 28 patients (11 female and 17 male) in the
AMD/ERM group. The mean age was 66.3 ± 9.9 years in the
AMD group and 68.6 ± 9.4 years in the AMD/ERM group.
The baseline information of the groups, including the demo-
graphic data and ocular characteristics, is listed in Table 1. No
baseline parameter significantly differed between the groups.
Mean BCVA values at baseline and at the 3-, 6-, 12-,
and 24-month follow-up were listed in Table 2. There was no
significant difference in the BCVA improvement between the
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Table 1: Comparison of patient demographics and characteristics of the AMD and AMD/ERM groups at baseline.
AMD group AMD/ERM group 𝑃 value
Number of patients 35 28 —
Mean age, years ± SD (range)∗ 66.3 ± 9.9(52–84)
68.6 ± 9.4
(55–85) 0.38
Gender (female/male)† 15/20 11/17 0.77
CNV type classic/nonclassic† 12/23 11/17 0.68
Mean BCVA, logMAR ± SD (range)∗ 0.71 ± 0.28(0.3–1.3)
0.73 ± 0.31
(0.3–1.3) 0.88
Mean CRT, 𝜇m ± SD (range)∗ 315 ± 102(275–462)
371 ± 95
(298–519) 0.06
PED (%)† 16 (45%) 9 (32%) 0.27
AMD, age-related macular degeneration; ERM, epiretinal membrane; BCVA, best corrected visual acuity; CRT, central retinal thickness; PED, pigment
epithelium detachment; SD, standard deviation.
∗Mann-Whitney 𝑈 test.
†Chi-square test.
Table 2: Mean best corrected visual acuity and central retinal thickness values at baseline and at the 3-, 6-, 12-, and 24-month follow-up for
AMD and AMD/ERM groups.
AMD group 𝑃 value AMD/ERMgroup 𝑃 value
Mean baseline BCVA, logMAR ± SD (range) 0.71 ± 0.28(0.3–1.3)
0.73 ± 0.31
(0.3–1.3)
Mean BCVA at 3 months, logMAR ± SD (range) 0.61 ± 0.22(0.2–1.0) 0.02
0.64 ± 0.32
(0.3–1.1) 0.03
Mean BCVA at 6 months, logMAR ± SD (range) 0.63 ± 0.21(0.3–1.0) 0.11
0.66 ± 0.31
(0.3–1.1) 0.13
Mean BCVA at 12 months, logMAR ± SD (range) 0.63 ± 0.22(0.3–1.0) 0.13
0.67 ± 0.28
(0.3–1.2) 0.21
Mean BCVA at 24 months, logMAR ± SD (range) 0.66 ± 0.24(0.3–1.0) 0.39
0.70 ± 0.25
(0.3–1.3) 0.52
Mean baseline CRT, 𝜇m ± SD (range) 315 ± 102(275–462)
371 ± 95
(298–519)
Mean CRT at 3 months, 𝜇m ± SD (range) 224 ± 63(172–284) <0.001
301 ± 86
(221–353) <0.001
Mean CRT at 6 months, 𝜇m ± SD (range) 257 ± 71(178–299) <0.001
322 ± 90
(263–367) <0.001
Mean CRT at 12 months, 𝜇m ± SD (range) 245 ± 73(160–312) <0.001
311 ± 67
(232–380) <0.001
Mean CRT at 24 months, 𝜇m ± SD (range) 225 ± 62(153–302) <0.001
314 ± 77
(240–391) <0.001
AMD, age-relatedmacular degeneration; ERM, epiretinalmembrane; BCVA, best corrected visual acuity; CRT, central retinal thickness; SD, standard deviation.
∗One-way ANOVA test for all comparisons.
groups at the 3-, 6-, 12-, and 24-month follow-up (𝑃 = 0.29,
𝑃 = 0.88, 𝑃 = 0.74, 𝑃 = 0.85, resp.) (Figure 1).
In the AMD group, BCVA did not change (±5 ETDRS
letters) in 22 eyes (63%), improved >5 ETDRS letters in 9
eyes (26%), and decreased >5 ETDRS letters in 4 eyes (11%) at
24 months. In the AMD/ERM group, BCVA did not change
(±5 ETDRS letters) in 16 eyes (57%), improved >5 letters in 7
eyes (25%), and decreased >5 ETDRS letters in 5 eyes (18%) at
24 months. Distribution of changes in BCVA (maintenance,
improvement, or decrease of BCVA) was not statistically
significant between the groups (𝑃 = 0.65, 𝑃 = 0.94, 𝑃 = 0.47,
resp.).
Mean CRT values at baseline and at the 3-, 6-, 12-, and 24-
month follow-up were listed in Table 2. The mean change in
CRT was not statistically different between the groups at the
3-, 6-, 12-, and 24-month follow-up (𝑃 = 0.13, 𝑃 = 0.52, 𝑃 =
0.94, 𝑃 = 0.17, resp.) (Figure 2).
Themean number of injections performed per eye during
24-month follow-upwas 8.8 (range from 3 to 15) for the AMD
group and 9.2 (range from 3 to 16) for the AMD/ERM group.
This difference was not statistically different between the
groups (𝑃 = 0.76). During the following 21months after three
initial loading doses, 3 patients (8%) in the AMD group and
only one patient (3%) in the AMD/ERM group did not
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3 months 6 months 12 months 24 months
AMD group 0.09 0.06 0.06 0.03





































Figure 1: Change in best corrected visual acuity (logMAR) from baseline and to the 3-, 6-, 12-, and 24-month follow-up in the AMD group
and AMD/ERM group. (Respective intravitreal injections administered at months 0, 1, and 2 and then as per treatment protocol.)
3 months 6 months 12 months 24 months
AMD group 91 65 70 81


































Figure 2: Change in central retinal thickness (𝜇m) from baseline and to the 3-, 6-, 12-, and 24-month follow-up in the AMD group and
AMD/ERM group. (Respective intravitreal injections administered at months 0, 1, and 2 and then as per treatment protocol.)
require further treatment. During the 24-month follow-up,
no serious injection- or drug-related ocular or systemic adv-
erse events were observed.
4. Discussion
In this study, we compared the visual and anatomical out-
comes and frequency of injections of an as-needed treatment
regimen following a loading dose of three initial injections
with bevacizumab between patients with nAMD without an
ERMand thosewith anERM.By 24months, similar improve-
ments in both groups for BCVA occurred after the initial
loading dose and then showed a gradual decrease through
the study. The comparison of AMD treatment trials (CATT)
was the first trial to provide evidence supporting the use of
bevacizumab therapy in nAMD [17]. In the CATT, patients
were randomly assigned to receive intravitreal ranibizumab
or bevacizumab on a monthly schedule or on an as-needed
treatment regimen which was largely driven by fluid onOCT.
TheCATT 2-year report showed that as-needed bevacizumab
group gained 5 ETDRS letters (equal to 0.1 logMAR) com-
pared to baseline. In our study, both AMD and AMD/ERM
groups achieved lower gains in BCVA at 24 months than
CATT. In the CATT, mean baseline letter score was 60
ETDRS letters (equal to 0.5 logMAR) which is better than
that of the present study with the values of 0.7 logMAR for
AMD group and 0.73 logMAR for AMD/ERM group. In our
study, worse baseline visual acuity levels may be responsible
for lower VA gain than CATT.
A significant reduction in the baseline CRT values in both
groups reflected the efficacy of IVB even in the presence of
ERM. The reduction in CRT after an anti-VEGF injection is
primarily the result of the reduced permeability of the neova-
scular lesion, with a subsequent reduction in intra- and
subretinal fluid levels [18]. In our study, the two groups
differed in mean CRT at baseline, but this difference was not
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statistically significant. Previous studies revealed that patients
with macular edema secondary to epiretinal membranes had
both cystic and noncystic changes on OCT images that result
in increased CRT values [19]. In addition, Chen et al. found
that intravitreal bevacizumab injection had no beneficial
effect on CRT improvement for eyes with persistent macular
edema after idiopathic macular ERM removal [20]. Thus, we
suggest that the higher consistency of CRT values in the
AMD-ERM group than in the AMD group throughout the
study period likely resulted from ERM-related macular
edema.
Different doses and treatment protocols have been uti-
lized in the management of CNV with bevacizumab. Most
regimens involve an as-needed or PRN regimen. This may
include one to three loading doses which was followed
by an as-needed treatment phase based on OCT and FA
changes [8–10]. As such, the best criteria for retreatment are
uncertain, particularly in the presence of an ERM. When
considering retreatment in nAMD, FA has been shown to
be unable to differentiate between leakage and staining,
and poor agreement persists in the interpretation of FA in
nAMDamong physicians [21, 22].We also commented on the
difficulty of correctly identifying leakage due to CNV in the
presence of ERM, which can confound the interpretation of
FA images. Fluid can accumulate in the subretinal or sub-RPE
spaces or between all layers of the inner retina and can be
quantitatively evaluated with OCT. It has been suggested that
subretinal fluidmay be amore sensitive and clinically relevant
parameter to guide treatment regimens than CRT. In a study
by Golbaz et al., a manual segmentation analysis using SD-
OCT of the intra- and subretinal compartments in nAMD
revealed an immediate and accentuated response in subreti-
nal fluid values during anti-VEGF therapy [23]. Furthermore,
as noted in previous studies, larger CNV area and presence
of GA were independently associated with less improvement
in VA [24]. It is important to note that the discrimination of
intra- or subretinal fluid and such variables between the
groups could not be employed in this study because of its
retrospective design. We are aware that this would affect our
results.
After the loading phase, the eyes respondingminimally or
with no anatomic or functional improvement to two consec-
utive injections of bevacizumab in the AMD/ERM group
did not receive further therapy until the retreatment criteria
were met. Because further injections may not be of benefit
in this case, we assumed that unnecessary reinjections could
be eliminated by this way in the presence of an ERM. In this
study, both groups required a similar number of injections on
as-needed treatment regimen during the study period. These
results suggest that a retreatment strategy based on OCT
can be implemented with anti-VEGF agents when making
retreatment decisions even in the presence of ERM.
Several published studies have shown a higher rate of
abnormalities of the vitreomacular interface, including
ERMs, retinal thickening, and retinal distortion, in patients
with AMD compared to those without AMD [25–27]. Pierro
et al. showed that an ERM was present in 26% to 32% of eyes
with nAMD [15]. It has been speculated that chronic traction
on the retina may cause the degeneration or alteration of the
retinal pigment epithelium or Bruch membrane. Mechanical
traction may create low-grade inflammation and stimulate
the induction or progression of nAMD by inducing the
continued release of VEGF [28].
According to the theory for the role of mechanical factors
in ERMs local forces induce a release of mediators that lead
to a breakdown of the blood-retinal barrier, resulting in
macular edema [13]. Furthermore, these tractional forcesmay
antagonize the effects of anti-VEGF treatments and cause
pharmacological resistance in those patients [29, 30]. Unfor-
tunately, no published study has investigated whether there is
an increase in vitreous VEGF levels in the presence of vitreo-
retinal interface pathologies or an alteration in the penetra-
tion of anti-VEGF drugs through the ERM in eyes with
nAMD. Luttrull and Spink showed that vitrectomywith ERM
peeling may provide visual improvement in selected patients
with nAMD after initiation of anti-VEGF therapy in a
small, uncontrolled, nonrandomized, and retrospective study
[31]. Similarly, Mojana et al. found that vitrectomy may be
beneficial to improve vision in some of the patients with vitre-
omacular traction who do not respond to anti-VEGF therapy
for nAMD [30]. However, this series had a small number
of patients to conclude. In addition, vitrectomy in such
eyes can result in complications andmay also complicate anti-
VEGF treatment, as itmay shortens the half-life of intravitreal
anti-VEGF drugs, so that higher doses and more frequent
injections of anti-VEGF drugsmay be needed postoperatively
[32, 33]. Based on these findings, none of the patients in
our study had vitrectomy for ERM peeling during the study
period.
The results of this study should be interpreted with con-
sideration of the retrospective data collection and the small
number of patients. Further studies will be helpful for under-
standing how ERM and vitreoretinal surface disorders affect
the dosing strategy of anti-VEGF agents and the course of
nAMD in the presence of ERM.
In summary, the presence of an ERM can be an additional
cause of macular edema in nAMD patients and should also
be considered in clinical practice. While the quantitative
measurement of retinal thickness by OCT has been used as
a retreatment criterion in neovascular AMD therapies, the
qualitative evaluation and detection of vitreoretinal interface
abnormalities have been important in decisions regarding
treatment with intravitreal antiangiogenic agents.
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